CS3006

CStone Pharmaceuticals · Phase 1 active Small molecule

At a glance

Generic name	CS3006
Also known as	MEK inhibitor
Sponsor	CStone Pharmaceuticals
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CS3006 CI brief — competitive landscape report
CS3006 updates RSS · CI watch RSS
CStone Pharmaceuticals portfolio CI